Seek Returns

MEDP vs. RPRX: Medpace vs. Royalty Pharma Stock Comparison

How do Medpace (MEDP) and Royalty Pharma (RPRX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Medpace (MEDP) and Royalty Pharma (RPRX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MEDP is classified in Life Sciences Tools & Services while RPRX is classified in Pharmaceuticals.

Company profile comparison for Medpace (MEDP) and Royalty Pharma (RPRX)
Profile ItemMEDPRPRX
NameMedpace Holdings, Inc.Royalty Pharma plc Class A Ordinary Shares
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesPharmaceuticals
GICS Sub-IndustryLife Sciences Tools & ServicesPharmaceuticals
Market Capitalization18.27 billion USD38.70 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateAugust 11, 2016June 16, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

MEDP
RPRX
GSPC
Loading price history…
Medpace (MEDP) vs. Royalty Pharma (RPRX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Medpace (MEDP) and Royalty Pharma (RPRX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Medpace (MEDP) and Royalty Pharma (RPRX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Medpace (MEDP) and Royalty Pharma (RPRX)
MetricMEDPRPRX
Total Return (1Y)13.29%81.08%
Total Return (3Y, Annualized)35.26%39.21%
Total Return (5Y, Annualized)24.49%14.22%

Risk Profile

Drawdown History

MEDP
RPRX
GSPC
Loading price history…
Medpace (MEDP) vs. Royalty Pharma (RPRX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Medpace (MEDP) and Royalty Pharma (RPRX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Medpace (MEDP) and Royalty Pharma (RPRX)
MetricMEDPRPRX
Volatility (1Y, Annualized)44.16%22.05%
Beta (5Y)1.100.36
Max Drawdown (5Y)-42.87%-41.98%
Avg. Volume (3M)258.39K3.10M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
MEDP and RPRX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Medpace (MEDP) and Royalty Pharma (RPRX)
MetricMEDPRPRX
Sharpe Ratio (1Y)0.203.48
Sortino Ratio (1Y)0.265.72

Profitability

ROE (TTM)

Both companies show strong equity returns, but Medpace (MEDP) at 117.88% is the standout with ROE above its industry range; Royalty Pharma (RPRX) at 12.09% also sits in the top quartile.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.88%

MEDP
117.88%
Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.09%

Max
109.18%
RPRX
12.09%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Medpace (MEDP) vs. Royalty Pharma (RPRX): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Medpace (MEDP) at 18.24% and Royalty Pharma (RPRX) at 25.70% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.24%

MEDP
18.24%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.70%

RPRX
25.70%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Medpace (MEDP) vs. Royalty Pharma (RPRX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Medpace (MEDP) at 23.12% and Royalty Pharma (RPRX) at 81.32% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.12%

Max
83.12%
MEDP
23.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

81.32%

Max
83.12%
RPRX
81.32%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Medpace (MEDP) vs. Royalty Pharma (RPRX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Medpace (MEDP) and Royalty Pharma (RPRX)
MetricMEDPRPRX
ROE (TTM)117.88%12.09%
ROA (TTM)18.71%5.43%
Net Margin (TTM)18.24%25.70%
Operating Margin (TTM)23.12%81.32%
Gross Margin (TTM)72.24%99.79%

Growth

Revenue Growth

Both Medpace (MEDP) at 19.97% and Royalty Pharma (RPRX) at 5.06% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Medpace (MEDP) vs. Royalty Pharma (RPRX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Medpace (MEDP) at 20.98% and Royalty Pharma (RPRX) at 23.09% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Medpace (MEDP) vs. Royalty Pharma (RPRX): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Medpace (MEDP) and Royalty Pharma (RPRX)
MetricMEDPRPRX
Revenue Growth (YoY)19.97%5.06%
Revenue Growth (3Y CAGR)20.12%2.06%
EPS Growth (YoY)20.98%23.09%
EPS Growth (3Y CAGR)28.04%161.10%

Financial Strength

Current Ratio (MRQ)

Both Medpace (MEDP) at 0.83 and Royalty Pharma (RPRX) at 1.29 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
MEDP
0.83
Min
0.10

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.29

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
RPRX
1.29
Min
0.10
Loading chart…
Medpace (MEDP) vs. Royalty Pharma (RPRX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Medpace (MEDP) at 0.29 carries an industry-typical debt-to-equity mix, while Royalty Pharma (RPRX) at 0.88 uses more debt funding than most peers.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.29

Max
1.42
Q3
0.65
MEDP
0.29
Median
0.15
Q1
0.02
Min
0.00

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.88

Max
1.42
RPRX
0.88
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Medpace (MEDP) vs. Royalty Pharma (RPRX): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Medpace (MEDP) and Royalty Pharma (RPRX)
MetricMEDPRPRX
Current Ratio (MRQ)0.831.29
Debt / Equity (MRQ)0.290.88
Net Debt / EBITDA-0.844.76

Dividends

Dividend Yield (TTM)

Medpace (MEDP) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a yield of 1.37%, ranking against industry peers normally.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.37%

RPRX
1.37%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Medpace (MEDP) vs. Royalty Pharma (RPRX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Medpace (MEDP) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a payout of 60.46%, ranking against industry peers normally.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

60.46%

RPRX
60.46%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Medpace (MEDP) vs. Royalty Pharma (RPRX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Medpace (MEDP) and Royalty Pharma (RPRX)
MetricMEDPRPRX
Dividend Yield (TTM)0.00%1.37%
Dividend Payout Ratio (TTM)0.00%60.46%

Valuation

P/E Ratio (TTM)

Medpace (MEDP) at 36.26 is near its industry’s usual P/E ratio, while Royalty Pharma (RPRX) at 43.99 sits in the richer quartile — RPRX needs stronger growth or earnings quality to justify the premium.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.26

Max
85.34
Q3
43.46
MEDP
36.26
Median
26.69
Q1
13.30
Min
0.07

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.99

Max
85.34
RPRX
43.99
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Medpace (MEDP) vs. Royalty Pharma (RPRX): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Medpace (MEDP) at 6.44 and Royalty Pharma (RPRX) at 14.79 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.44

Max
58.18
Q3
25.77
Median
7.30
MEDP
6.44
Q1
3.01
Min
0.01

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.79

Max
58.18
Q3
25.77
RPRX
14.79
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Medpace (MEDP) vs. Royalty Pharma (RPRX): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Royalty Pharma (RPRX) at 4.39 sits near its industry’s typical P/B ratio, while Medpace (MEDP) at 31.23 prices above its benchmark range — MEDP looks rich relative to book.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.23

MEDP
31.23
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.39

Max
13.53
Q3
6.54
RPRX
4.39
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Medpace (MEDP) vs. Royalty Pharma (RPRX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Medpace (MEDP) and Royalty Pharma (RPRX)
MetricMEDPRPRX
P/E Ratio (TTM)36.2643.99
P/S Ratio (TTM)6.4414.79
P/B Ratio (MRQ)31.234.39
Free Cash Flow Yield (TTM)2.72%-1.16%